Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which amyloid deposition, tau pathology, neuroinflammation, and age-related metabolic decline interact across biological scales. Microglia occupy a central position in this network by sensing protein aggregates, remodeling synapses, clearing debris, and coordinating inflammatory signaling. Growing evidence from animal models, human postmortem tissue, and induced pluripotent stem cell-derived microglia suggests that mitochondrial dysfunction may act not only because of microglial activation but also as an upstream determinant of microglial fate and inflammatory phenotype. AD-associated microglial states are linked to impaired oxidative phosphorylation, abnormal mitochondrial dynamics, defective mitophagy, mitochondrial DNA damage, excessive reactive oxygen species, and rerouting toward glycolytic or lipid-stressed immunometabolic programs. However, most evidence remains confined to single-omics studies, leaving the hierarchy linking genetic risk, transcriptional transitions, protein-network failure, and metabolic collapse incompletely resolved. Here, we synthesize genomic, transcriptomic, proteomic, metabolomic, and spatial evidence to propose a layered cross-omics framework for microglial mitochondrial dysfunction in AD and discuss its implications for biomarker development, patient stratification, and state-specific therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: